$ENGN

enGene Therapeutics Inc.

enGene Therapeutics is a clinical-stage biotechnology company developing non-viral genetic medicines for diseases affecting mucosal tissues and other organs. Its proprietary DDX gene delivery platform uses a chitosan-based carrier to deliver genetic material locally. The lead product candidate, detalimogene voraplasmid, is being studied as a monotherapy for high-risk non-muscle invasive bladder cancer, including disease that has not responded to BCG treatment. The company is also exploring other bladder cancer populations and preclinical applications of its platform. enGene is studying detalimogene in the Phase 1/2 LEGEND trial, which includes a pivotal cohort and additional patient groups. It makes drug candidates using its DDX platform and has developed manufacturing processes for detalimogene. The company owns development and commercialization rights to detalimogene. Its headquarters are in Saint-Laurent.

No enriched coverage for $ENGN in the last 7 days.

No SEC Form 4 filings for $ENGN in the last 30 days.

See all $ENGN insider activity →

ENGN sentiment & insider activity

Recent ENGN coverage spans financial news, market movers and earnings.

What's driving ENGN

AlphAI scores every news story that mentions ENGN with an AI model for sentiment and relevance, and aggregates insider trades from enGene Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ENGN

Score
$ENGNHighAI 8/10

Engene stock maintains Outperform rating on bladder cancer data

Raymond James reiterated an Outperform rating and $4.00 price target on Engene Holdings (ENGN) after positive bladder cancer trial data. The stock is down 79% from its 52-week high but has a strong balance sheet. The FDA meeting feedback and trial results suggest potential approval by 2026. Other analysts also commented on the company's prospects.

Here are Thursday's biggest analyst calls: Nvidia, SpaceX, AMD, Apple, Ulta, Disney & more

Analysts made several calls on Thursday. Bernstein reiterated Apple (AAPL) as outperform, citing its customer loyalty and growth. Piper Sandler downgraded General Mills (GIS) to neutral due to operating pressures. Barclays upgraded Reliance (RS) to overweight, expecting higher steel prices. Oppenheimer and Bernstein downgraded Nvidia (NVDA) due to leadership turmoil. KeyBanc upgraded Maravai Lifesciences (MRVI) to overweight, seeing it as a midterm winner.

enGene Therapeutics Inc. (ENGN): Results of Operations and Financial Condition

enGene Therapeutics Inc. (ENGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Corporate Presentation Non-Viral Genetic Medicine Disclaimers Cautionary Statement Regarding Forward-Looking Statements This Presentation contains certain forward-looking statements within the meaning of the federal securities laws and "forward-looking information" within the mea

H.C. Wainwright reiterates Engene stock rating on NMIBC data

H.C. Wainwright reiterated a Buy rating and $4.00 price target for Engene Holdings (NASDAQ:ENGN) after a webinar on detalimogene for non-muscle invasive bladder cancer. The stock is down 81% year-to-date but may be undervalued, with negative $104M levered free cash flow. Engene plans a pivotal-cohort update in Q4 2026 and potential FDA approval in 2027. Management also discussed preclinical data and a surfactant pre-rinse cohort. Citizens maintains a Market Perform rating.

Related tickers